Scholarlink

Background <p>Cervical cancer, primarily caused by sexually transmitted high-risk Human Papillomavirus (HPV) infections, remains a major global health challenge. Despite significant advances in HPV vaccination and cervical cancer screening strategies, effective and non-invasive treatment options for HPV infections and cervical dysplasia. are still lacking. Current management strategies of cervical dysplasia vary from the “wait and see” strategy to surgical interventions. This scoping review aimed to map the existing evidence on the efficacy and safety of Coriolus Versicolor (CV)-based vaginal gel as a novel and effective non-invasive treatment of HPV infection and mild cervical dysplasia.</p> Methods <p>A comprehensive scoping review was performed using systematic searches in PubMed, Embase, EBSCOhost, Ovid, CNKI and SciELOdatabases. The literature search covered publications up to August 2025. Two reviewers independently screened possible studies, following the PRISMA guidelines for scoping reviews. Only human experimental randomized controlled trial (RCT) and observational cohort studies published in English, Norwegian, Swedish or Danish were considered.</p> Results <p>A total of 127 articles were screened, and five studies met the inclusion criteria: one RCT (<i>n</i> = 91), one sub-analysis of this RCT (<i>n</i> = 41), and three cohort studies (<i>n</i> = 183, 192, 21). Treatment with CV-based vaginal gel was associated with improved HPV clearance and regression of cervical dysplastic lesions, with regression rates of 76.1–84.9% in treated women compared 40.8–64.5% in untreated controls. Positive effects were also observed in women with hrHPV and in postmenopausal women. No serious adverse events were reported.</p> Conclusion <p>This scoping review suggests that CV-based vaginal gel shows promising but preliminary efficacy and safety in promoting regression of cervical dysplastic lesions and HPV clearance. Larger, long-term multinational RCT studies with standardized outcomes definitions are needed to confirm these preliminary findings and to establish the therapeutic role of the CVbased vaginal gel in clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of coriolus versicolor-based vaginal gel on clearance of human papillomavirus and cervical dysplasia - a scoping review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月8日

查看全文
  • Ida Birkbak Højen,
  • Mathilde Kristine Kristensen,
  • Vibe Munk Bertelsen,
  • Mette Tranberg,
  • Lone Kjeld Petersen,
  • Berit Andersen,
  • Pinar Bor

摘要

Background

Cervical cancer, primarily caused by sexually transmitted high-risk Human Papillomavirus (HPV) infections, remains a major global health challenge. Despite significant advances in HPV vaccination and cervical cancer screening strategies, effective and non-invasive treatment options for HPV infections and cervical dysplasia. are still lacking. Current management strategies of cervical dysplasia vary from the “wait and see” strategy to surgical interventions. This scoping review aimed to map the existing evidence on the efficacy and safety of Coriolus Versicolor (CV)-based vaginal gel as a novel and effective non-invasive treatment of HPV infection and mild cervical dysplasia.

Methods

A comprehensive scoping review was performed using systematic searches in PubMed, Embase, EBSCOhost, Ovid, CNKI and SciELOdatabases. The literature search covered publications up to August 2025. Two reviewers independently screened possible studies, following the PRISMA guidelines for scoping reviews. Only human experimental randomized controlled trial (RCT) and observational cohort studies published in English, Norwegian, Swedish or Danish were considered.

Results

A total of 127 articles were screened, and five studies met the inclusion criteria: one RCT (n = 91), one sub-analysis of this RCT (n = 41), and three cohort studies (n = 183, 192, 21). Treatment with CV-based vaginal gel was associated with improved HPV clearance and regression of cervical dysplastic lesions, with regression rates of 76.1–84.9% in treated women compared 40.8–64.5% in untreated controls. Positive effects were also observed in women with hrHPV and in postmenopausal women. No serious adverse events were reported.

Conclusion

This scoping review suggests that CV-based vaginal gel shows promising but preliminary efficacy and safety in promoting regression of cervical dysplastic lesions and HPV clearance. Larger, long-term multinational RCT studies with standardized outcomes definitions are needed to confirm these preliminary findings and to establish the therapeutic role of the CVbased vaginal gel in clinical practice.